Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600-mutant melanoma treated with first-line spartalizumab (S) plus dabrafenib (D) plus trametinib (T).

R Dummer; D Gusenleitner; CD Campbell; C Lebbe; V Atkinson; M Mandala; PD Nathan; A Arance; Erika Richtig; N Yamazaki; C Robert; D Schadendorf; HAH Tawbi; PA Ascierto; A Ribas; K Flaherty; E Gasal; JC Brase; GV Long

Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600-mutant melanoma treated with first-line spartalizumab (S) plus dabrafenib (D) plus trametinib (T).

R Dummer
, D Gusenleitner
, CD Campbell
, C Lebbe
, V Atkinson
, M Mandala
, PD Nathan
, A Arance
, Erika Richtig
, N Yamazaki
, C Robert
, D Schadendorf
, HAH Tawbi
, PA Ascierto
, A Ribas
, K Flaherty
, E Gasal
, JC Brase
, GV Long

Universitätsklinik für Dermatologie und Venerologie

Publikation: Beitrag in Fachzeitschrift › Konferenzabstract

2 Quellenangaben (Web of Science)

Originalsprache	Englisch
Fachzeitschrift	Journal of Clinical Oncology
Publikationsstatus	Veröffentlicht - 2020
Veranstaltung	American Society of Clinical Oncology and Society for Immunotherapy of Cancer Symposium 2020 - Orlando, USA/Vereinigte Staaten Dauer: 6 Feb. 2020 → 8 Feb. 2020

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gute Gesundheit und Wohlergehen

Wissenschaftszweige

302 Klinische Medizin

Andere Dateien und Links

Web of Science

Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600-mutant melanoma treated with first-line spartalizumab (S) plus dabrafenib (D) plus trametinib (T).
Dummer, R. (Autor*in), Gusenleitner, D. (Autor*in), Campbell, C. (Autor*in), Lebbe, C. (Autor*in), Atkinson, V. (Autor*in), Mandala, M. (Autor*in), Nathan, P. (Autor*in), Arance, A. (Autor*in), Richtig, E. (Autor*in), Yamazaki, N. (Autor*in), Robert, C. (Autor*in), Schadendorf, D. (Autor*in), Tawbi, H. (Autor*in), Ascierto, P. (Autor*in), Ribas, A. (Autor*in), Flaherty, K. (Autor*in), Gasal, E. (Autor*in), Brase, J. (Autor*in) & Long, G. (Autor*in)
2020
Aktivität: Vortrag oder Poster › Poster

Dieses zitieren

Dummer, R., Gusenleitner, D., Campbell, CD., Lebbe, C., Atkinson, V., Mandala, M., Nathan, PD., Arance, A., Richtig, E., Yamazaki, N., Robert, C., Schadendorf, D., Tawbi, HAH., Ascierto, PA., Ribas, A., Flaherty, K., Gasal, E., Brase, JC., & Long, GV. (2020). Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600-mutant melanoma treated with first-line spartalizumab (S) plus dabrafenib (D) plus trametinib (T). Journal of Clinical Oncology.

@article{d330e53c62ee4d3bbe8a34137f4ce3d3,

title = "Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600-mutant melanoma treated with first-line spartalizumab (S) plus dabrafenib (D) plus trametinib (T).",

author = "R Dummer and D Gusenleitner and CD Campbell and C Lebbe and V Atkinson and M Mandala and PD Nathan and A Arance and Erika Richtig and N Yamazaki and C Robert and D Schadendorf and HAH Tawbi and PA Ascierto and A Ribas and K Flaherty and E Gasal and JC Brase and GV Long",

year = "2020",

language = "English",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

note = "American Society of Clinical Oncology and Society for Immunotherapy of Cancer Symposium 2020, ASCO SITC 2020 ; Conference date: 06-02-2020 Through 08-02-2020",

}

Dummer, R, Gusenleitner, D, Campbell, CD, Lebbe, C, Atkinson, V, Mandala, M, Nathan, PD, Arance, A, Richtig, E, Yamazaki, N, Robert, C, Schadendorf, D, Tawbi, HAH, Ascierto, PA, Ribas, A, Flaherty, K, Gasal, E, Brase, JC & Long, GV 2020, 'Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600-mutant melanoma treated with first-line spartalizumab (S) plus dabrafenib (D) plus trametinib (T).', Journal of Clinical Oncology.

Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600-mutant melanoma treated with first-line spartalizumab (S) plus dabrafenib (D) plus trametinib (T). / Dummer, R; Gusenleitner, D; Campbell, CD et al.
in: Journal of Clinical Oncology, 2020.

Publikation: Beitrag in Fachzeitschrift › Konferenzabstract

TY - JOUR

T1 - Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600-mutant melanoma treated with first-line spartalizumab (S) plus dabrafenib (D) plus trametinib (T).

AU - Dummer, R

AU - Gusenleitner, D

AU - Campbell, CD

AU - Lebbe, C

AU - Atkinson, V

AU - Mandala, M

AU - Nathan, PD

AU - Arance, A

AU - Richtig, Erika

AU - Yamazaki, N

AU - Robert, C

AU - Schadendorf, D

AU - Tawbi, HAH

AU - Ascierto, PA

AU - Ribas, A

AU - Flaherty, K

AU - Gasal, E

AU - Brase, JC

AU - Long, GV

PY - 2020

Y1 - 2020

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000529994300041

M3 - Conference abstract

SN - 0732-183X

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

T2 - American Society of Clinical Oncology and Society for Immunotherapy of Cancer Symposium 2020

Y2 - 6 February 2020 through 8 February 2020

ER -

Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600-mutant melanoma treated with first-line spartalizumab (S) plus dabrafenib (D) plus trametinib (T).

UN SDGs

Wissenschaftszweige

Andere Dateien und Links

Aktivitäten

Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600-mutant melanoma treated with first-line spartalizumab (S) plus dabrafenib (D) plus trametinib (T).

Dieses zitieren